Working… Menu

Pharmacological Activation of HMN for OSA (OSA12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03640052
Recruitment Status : Recruiting
First Posted : August 21, 2018
Last Update Posted : November 19, 2018
Information provided by (Responsible Party):
Luigi Taranto Montemurro, Brigham and Women's Hospital

Brief Summary:
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201L, LTM1201LN, LTM1201LB, LTM1201LD administered before sleep on OSA phenotype traits and OSA severity during sleep.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Drug: Placebo oral capsule Drug: LTM1201L Drug: LTM1201LN Drug: LTM1201LB Drug: LTM1201LD Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea
Actual Study Start Date : October 30, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo capsule 1 time before bedtime
Drug: Placebo oral capsule
Placebo capsule before sleep

Active Comparator: LTM1201L
LTM1201L capsule 1 time before bedtime
Drug: LTM1201L
LTM1201L capsule before sleep

Active Comparator: LTM1201LN
LTM1201LN capsule 1 time before bedtime
Drug: LTM1201LN
LTM1201LN capsule before sleep

Active Comparator: LTM1201LB
LTM1201LB capsule 1 time before bedtime
Drug: LTM1201LB
LTM1201LB capsule before sleep

Active Comparator: LTM1201LD
LTM1201LD capsule 1 time before bedtime
Drug: LTM1201LD
LTM1201LD capsule before sleep

Primary Outcome Measures :
  1. Apnea hypopnea Index (AHI, average number of events for every hour of sleep) [ Time Frame: 1 night ]
    Based on previous studies the investigators anticipate that active comparators will reduce AHI more effectively in subjects with moderate sleep apnea and low-to-moderate collapsibility (Vpassive >50% of eupneic values). Higher AHI indicates more severe OSA, usually ranging between 10 to 110 events/hour.

Secondary Outcome Measures :
  1. Collapsibility of the upper airway: VPassive and VActive (ventilation as % of eupneic value) [ Time Frame: 1 night ]
    VPassive: ventilation when the ventilatory drive (estimated from flow trace with an algorithm) is low and pharyngeal dilator muscles are relatively passive. VActive: ventilation when ventilatory drive is high and pharyngeal dilator muscles are relatively active.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • AHI > 10 events/h during NREM supine sleep

Exclusion Criteria:

  • Any medical condition other than well controlled hypertension and mild diabetes.
  • Any medication known to influence breathing, sleep/arousal, or muscle physiology.
  • Claustrophobia.
  • Inability to sleep supine.
  • Allergy to any of the medications tested in the protocol.
  • History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D.
  • Individuals with underlying cardiac disease, such as arrhythmias.
  • Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of the studied medications for medical care.
  • For women: Pregnancy.
  • Pulmonary hypertension
  • Severe OSA with a mean SaO2 lower than 88%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03640052

Layout table for location information
United States, Massachusetts
Sleep Disorders Research Program Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Lauren Hess, RPSGT    617-732-8976   
Contact: Rebecca Salant    617-525-8888   
Principal Investigator: Luigi Taranto Montemurro, MD         
Sponsors and Collaborators
Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Luigi Taranto Montemurro, Principal investigator, Brigham and Women's Hospital Identifier: NCT03640052     History of Changes
Other Study ID Numbers: 2018P001201
First Posted: August 21, 2018    Key Record Dates
Last Update Posted: November 19, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases